Schizophrenia drug under scrutiny

Stephen Beard Jan 23, 2007
HTML EMBED:
COPY

Schizophrenia drug under scrutiny

Stephen Beard Jan 23, 2007
HTML EMBED:
COPY

TEXT OF STORY

MARK AUSTIN THOMAS: Leaked documents have shed new light on Zyprexa, a drug used in the treatment of schizophrenia. According to the London Times, the documents reveal the drug’s maker, Eli Lilly, has been worried for years about side effects from the drug. From London, Stephen Beard has the story.


STEPHEN BEARD: Zyprexa is the fifth best-selling drug in the world. Last year it generated 30 percent of Eli Lilly’s total revenues.

But it’s also costing the company dear. After a series of lawsuits Lilly has agreed to pay out more than $1 billion in compensation.

Litigants claimed they’d developed diabetes and other diseases after taking the drug. Another 1,200 law suits are continuing.

The company has consistently denied that Zyprexa causes diabetes, but the London Times says it has seen internal documents which suggest otherwise — that the company was aware of a link between the drug and diabetes eight years ago.

Eli Lilly says the documents are misleading. The company claims that after 23 years of research, the drug had been given a clean bill of health.

In London, this is Stephen Beard for Marketplace.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.